DE60037192D1 - Mittel zur verbesserung der erkrankungen nach zerebralen durchblutungsstörungen sowie zur verhinderung deren fortschrittens - Google Patents
Mittel zur verbesserung der erkrankungen nach zerebralen durchblutungsstörungen sowie zur verhinderung deren fortschrittensInfo
- Publication number
- DE60037192D1 DE60037192D1 DE60037192T DE60037192T DE60037192D1 DE 60037192 D1 DE60037192 D1 DE 60037192D1 DE 60037192 T DE60037192 T DE 60037192T DE 60037192 T DE60037192 T DE 60037192T DE 60037192 D1 DE60037192 D1 DE 60037192D1
- Authority
- DE
- Germany
- Prior art keywords
- medicine
- progress
- prevent
- cerebral blood
- blood disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP20587799 | 1999-07-21 | ||
JP20587799 | 1999-07-21 | ||
PCT/JP2000/004830 WO2001005428A1 (fr) | 1999-07-21 | 2000-07-19 | Methodes preventives contre la recurrence d'une insuffisance cerebrovasculaire, et agents destines a ameliorer des troubles causes par une insuffisance cerebrovasculaire et a inhiber leur evolution |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60037192D1 true DE60037192D1 (de) | 2008-01-03 |
DE60037192T2 DE60037192T2 (de) | 2008-05-15 |
Family
ID=16514222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60037192T Expired - Lifetime DE60037192T2 (de) | 1999-07-21 | 2000-07-19 | Mittel zur verbesserung der erkrankungen nach zerebralen durchblutungsstörungen sowie zur verhinderung deren fortschreitens |
Country Status (7)
Country | Link |
---|---|
US (3) | US6852743B1 (de) |
EP (2) | EP1197226B1 (de) |
JP (1) | JP2001089393A (de) |
AU (1) | AU6019700A (de) |
CA (1) | CA2379666C (de) |
DE (1) | DE60037192T2 (de) |
WO (1) | WO2001005428A1 (de) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001005428A1 (fr) * | 1999-07-21 | 2001-01-25 | Takeda Chemical Industries, Ltd. | Methodes preventives contre la recurrence d'une insuffisance cerebrovasculaire, et agents destines a ameliorer des troubles causes par une insuffisance cerebrovasculaire et a inhiber leur evolution |
US20040097565A1 (en) * | 2001-01-29 | 2004-05-20 | Terashita Zen-Ichi | Analgesic and antiinflammatory drugs |
CA2456034A1 (en) * | 2001-08-03 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Sustained-release medicines |
AU2002364381A1 (en) * | 2001-11-23 | 2003-06-10 | Solvay Pharmaceuticals Gmbh | Hypertonia treatment during the acute phase of a cerebrovascular accident |
EP1452176A4 (de) * | 2001-12-03 | 2009-01-21 | Takeda Pharmaceutical | Mittel zur verbesserung der insulinresistenz |
JP4484427B2 (ja) * | 2001-12-03 | 2010-06-16 | 武田薬品工業株式会社 | インスリン抵抗性改善剤 |
TWI299663B (en) * | 2002-05-14 | 2008-08-11 | Novartis Ag | Methods of treatment |
ATE551056T1 (de) * | 2002-12-27 | 2012-04-15 | Takeda Pharmaceutical | Mittel zur hemmung der körpergewichtszunahme |
AU2004208615C1 (en) * | 2003-01-31 | 2010-05-13 | Daiichi Sankyo Company, Limited | Medicine for prevention of and treatment for arteriosclerosis and hypertension |
JP5100039B2 (ja) * | 2003-01-31 | 2012-12-19 | 第一三共株式会社 | 動脈硬化及び高血圧症の予防及び治療のための医薬 |
CN1798557A (zh) * | 2003-05-29 | 2006-07-05 | 协和梅迪克斯株式会社 | 抗抑郁剂或者抗抑郁用饮食品 |
TW200523257A (en) * | 2003-09-26 | 2005-07-16 | Novartis Ag | Use of organic compounds |
KR20130135994A (ko) * | 2005-06-27 | 2013-12-11 | 다이이찌 산쿄 가부시키가이샤 | 안지오텐신 ⅱ 수용체 길항제 및 칼슘 채널 차단제를 함유한 약학 제제 |
TWI399223B (zh) * | 2006-09-15 | 2013-06-21 | Daiichi Sankyo Co Ltd | 奧美沙坦酯及氨氯地平之固體劑型 |
US7747551B2 (en) * | 2007-02-21 | 2010-06-29 | Neurovista Corporation | Reduction of classification error rates and monitoring system using an artificial class |
US9066936B2 (en) * | 2007-03-28 | 2015-06-30 | Takeda Pharmaceutical Company Limited | Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL95975A (en) * | 1989-10-24 | 1997-06-10 | Takeda Chemical Industries Ltd | N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them |
US5250554A (en) * | 1989-10-24 | 1993-10-05 | Takeda Chemical Industries, Ltd. | Benzimidazole derivatives useful as angiotensin II inhibitors |
US5196444A (en) * | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
GB9110636D0 (en) * | 1991-05-16 | 1991-07-03 | Glaxo Group Ltd | Chemical compounds |
DE4142366A1 (de) * | 1991-07-15 | 1993-06-24 | Thomae Gmbh Dr K | Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
DE4123341A1 (de) | 1991-07-15 | 1993-01-21 | Thomae Gmbh Dr K | Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
DE4219534A1 (de) * | 1992-02-19 | 1993-12-16 | Thomae Gmbh Dr K | Substituierte Biphenylylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
GB9223860D0 (en) * | 1992-11-13 | 1993-01-06 | Glaxo Group Ltd | Chemical compounds |
US5721263A (en) * | 1993-06-07 | 1998-02-24 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for angiotensin II-mediated diseases |
CZ154994A3 (en) * | 1993-07-02 | 1995-09-13 | Senju Pharma Co | Visual hypotensive agent |
WO1997037688A2 (en) * | 1996-04-05 | 1997-10-16 | Takeda Chemical Industries, Ltd. | Pharmaceutical combination containing a compound having angiotensin ii and antagonistic activity |
US6177587B1 (en) | 1997-05-26 | 2001-01-23 | Takeda Chemical Industries, Ltd. | Production method of aminobenzene compound |
WO1999065500A1 (en) * | 1998-06-17 | 1999-12-23 | Bristol-Myers Squibb Company | Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination |
PT1096932E (pt) * | 1998-07-10 | 2007-09-21 | Novartis Pharma Ag | ''combinação anti-hipertensiva de valsartan e bloqueadores do canal de cálcio'' |
FR2783422A1 (fr) * | 1998-09-21 | 2000-03-24 | Sanofi Sa | Composition pharmaceutique contenant un antagoniste des recepteurs at1 de l'angiotensine ii et un antiagregant plaquettaire |
WO2001005428A1 (fr) * | 1999-07-21 | 2001-01-25 | Takeda Chemical Industries, Ltd. | Methodes preventives contre la recurrence d'une insuffisance cerebrovasculaire, et agents destines a ameliorer des troubles causes par une insuffisance cerebrovasculaire et a inhiber leur evolution |
DE10230272A1 (de) * | 2002-07-05 | 2004-01-22 | Solvay Pharmaceuticals Gmbh | AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen |
-
2000
- 2000-07-19 WO PCT/JP2000/004830 patent/WO2001005428A1/ja active IP Right Grant
- 2000-07-19 JP JP2000223871A patent/JP2001089393A/ja active Pending
- 2000-07-19 US US10/031,398 patent/US6852743B1/en not_active Expired - Fee Related
- 2000-07-19 EP EP00946393A patent/EP1197226B1/de not_active Expired - Lifetime
- 2000-07-19 DE DE60037192T patent/DE60037192T2/de not_active Expired - Lifetime
- 2000-07-19 EP EP07017024A patent/EP1867342A1/de not_active Withdrawn
- 2000-07-19 CA CA002379666A patent/CA2379666C/en not_active Expired - Fee Related
- 2000-07-19 AU AU60197/00A patent/AU6019700A/en not_active Abandoned
-
2004
- 2004-12-01 US US11/000,425 patent/US20050096382A1/en not_active Abandoned
-
2010
- 2010-01-29 US US12/696,620 patent/US20100120800A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1197226A4 (de) | 2003-01-07 |
WO2001005428A1 (fr) | 2001-01-25 |
US6852743B1 (en) | 2005-02-08 |
EP1867342A1 (de) | 2007-12-19 |
US20050096382A1 (en) | 2005-05-05 |
CA2379666C (en) | 2009-10-13 |
EP1197226B1 (de) | 2007-11-21 |
US20100120800A1 (en) | 2010-05-13 |
CA2379666A1 (en) | 2001-01-25 |
EP1197226A1 (de) | 2002-04-17 |
JP2001089393A (ja) | 2001-04-03 |
AU6019700A (en) | 2001-02-05 |
DE60037192T2 (de) | 2008-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60037192D1 (de) | Mittel zur verbesserung der erkrankungen nach zerebralen durchblutungsstörungen sowie zur verhinderung deren fortschrittens | |
EP1231864A4 (de) | Am gewebe befestigbarer medikamentenverabreichungskatheter und methode zu deren anwendung | |
EE04852B1 (et) | C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel | |
NO20003051D0 (no) | Metode for administrering av AspB28-humant insulin | |
PL1641918T3 (pl) | Komórki poporodowe do zastosowania w leczeniu choroby serca i układu krążenia | |
BR9707489A (pt) | Composto composição farmacêutica e processo para tratar um paciente sofrendo de um distúrbio fisilógico | |
IL127943A0 (en) | Pharmaceutical and cosmetic composition for the treatment of skin disorders | |
EE05067B1 (et) | Aminoproplfosfiinhapped ning nende kasutamine meditsiinis | |
ATE456954T1 (de) | Pharmazeutische zusammenstellung zur verwendung in notbehandlungen und dessen herstellungsverfahren | |
ID27576A (id) | Penggunaan siklosporin dalam pengobatan penyakit-penyakit peradangan autoimun | |
EP1187604A4 (de) | Verbindungen und methoden zur behandlung von störungen duch post-traumatischen stress | |
IL149360A0 (en) | Method and compositions for administering taxanes orally to human patients | |
EP1114862A3 (de) | Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankungen sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen | |
AU6539000A (en) | Composition and method for treating disease by increasing activated alpha2 macroglobulin in the blood and extravascular tissue | |
BR9510015A (pt) | Composto composição farmacéutica e processo para o tratamento de doenças enfecciosas em terapia humana ou veterinária | |
FR2799650B1 (fr) | Procede pour limiter la penetration dans la peau et/ou les fibres keratiniques d'un agent cosmetique et/ou pharmaceutique actif | |
DE60142584D1 (de) | Multilumen katheter und implantate zur verabreichung von therapeutischen substanzen an gewebe | |
NO20000376D0 (no) | Transdermalt terapeutisk system for frigiving av virkestoff gjennom huden inn i en organisme og fremgangsmåte for påfoering på huden | |
GB0312566D0 (en) | Veterinary composition for the topical treatment of traumatized or inflamed skin | |
GB9908059D0 (en) | Diagnosis and treatment of diseases | |
WO2001019359A3 (en) | Medicaments containing pantothenic acid for the treatment of inflammatory joint disease | |
EE200200348A (et) | Ravimkoostis kasutamiseks valu ravis | |
ATE309793T1 (de) | Superfizielles therapeutisches system zur topischen applikation von acetylsalicylsäure zur behandlung von akne-erkrankungen | |
EP1420776A4 (de) | Arzneimittel zur behandlung von hirnverletzungen und anwendungsverfahren dafür | |
ITMI992566A0 (it) | Composizione dermatologica per il trattamento topico di malattie cutan ee |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |